Scarica l'app Stockscreener
56.07
2.89%
-1.67
Precedente Chiudi:
$57.74
Aprire:
$58.11
Volume 24 ore:
408.51K
Relative Volume:
0.89
Capitalizzazione di mercato:
$3.45B
Reddito:
$112.53M
Utile/perdita netta:
$-258.91M
Rapporto P/E:
-12.95
EPS:
-4.33
Flusso di cassa netto:
$-124.42M
1 W Prestazione:
-1.09%
1M Prestazione:
-2.52%
6M Prestazione:
+23.56%
1 anno Prestazione:
+14.87%
Intervallo 1D:
$55.99
$58.45
Intervallo di 1 settimana:
$55.99
$58.45
Portata 52W:
$35.17
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Nome
Rhythm Pharmaceuticals Inc
Settore
Industria
Telefono
857-264-4280
Indirizzo
222 BERKELEY STREET, BOSTON, MA
Confronta RYTM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
56.07 | 3.45B | 112.53M | -258.91M | -124.42M | -4.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-02 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Oppenheimer | Outperform |
| 2024-10-21 | Iniziato | Guggenheim | Buy |
| 2024-09-18 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-08-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-05 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Reiterato | Needham | Buy |
| 2022-03-02 | Ripresa | Stifel | Buy |
| 2022-02-17 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Ripresa | Goldman | Neutral |
| 2021-08-04 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-01-08 | Iniziato | Goldman | Sell |
| 2019-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2019-07-08 | Iniziato | Canaccord Genuity | Buy |
| 2019-03-13 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-09-07 | Ripresa | Morgan Stanley | Overweight |
| 2018-06-25 | Reiterato | Needham | Buy |
| 2018-06-15 | Reiterato | Needham | Buy |
| 2017-10-30 | Iniziato | BofA/Merrill | Buy |
| 2017-10-30 | Iniziato | Needham | Buy |
Mostra tutto
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.
Cannon Financial Strategists Inc. Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns “Buy” Rating from Needham & Company LLC - Defense World
David P. Meeker Sells 9,896 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock - MarketBeat
Hunter C. Smith Sells 2,215 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee Sells 2,035 Shares - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German Sells 635 Shares - MarketBeat
Rhythm Pharmaceuticals (RYTM) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Rhythm Pharmaceuticals CAO Christopher German sells $36,334 in stock By Investing.com - Investing.com Australia
Needham & Company LLC Reiterates "Buy" Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals EVP sells stock worth $116,442 By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals (RYTM) Expected to Announce Quarterly Earnings on Thursday - Defense World
Rhythm pharmaceuticals CTO Joseph Shulman sells $70,266 in stock - Investing.com India
Rhythm Pharmaceuticals CEO David Meeker sells $566,249 in stock - Investing.com India
Rhythm Pharmaceuticals CAO Christopher German sells $36,334 in stock - Investing.com India
Rhythm Pharmaceuticals CFO sells $126,742 in stock By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals CFO sells $126,742 in stock - Investing.com
Rhythm Pharmaceuticals' chief human resources officer sells $56,190 in stock - Investing.com
Rhythm Pharmaceuticals CEO David Meeker sells $566,249 in stock By Investing.com - Investing.com UK
Rhythm Pharmaceuticals Executives Sell Shares - TradingView
(RYTM) Technical Pivots with Risk Controls - Stock Traders Daily
7 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know - Benzinga
Buy Recommendation for Rhythm Pharmaceuticals: Promising Potential of Imcivree in Obesity Treatment - TipRanks
Investors in Rhythm Pharmaceuticals (NASDAQ:RYTM) have seen fantastic returns of 577% over the past three years - Simply Wall St
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee Sells 1,815 Shares - MarketBeat
Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock? - MSN
Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 794 Shares of Stock - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells $246,773.99 in Stock - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells $74,532.96 in Stock - MarketBeat
Rhythm Pharmaceuticals Executives Conduct Stock Transactions - TradingView
abrdn plc Sells 32,287 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Needham & Company LLC Weighs in on RYTM FY2029 Earnings - MarketBeat
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on ... - The Bakersfield Californian
Rhythm Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Rare Disease Leader Rhythm Pharmaceuticals Sets Double Investor Events: Q4 Results & Major Healthcare Conference - StockTitan
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $68.09 Consensus Target Price from Analysts - Defense World
Research Analysts Set Expectations for RYTM FY2029 Earnings - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells 1,678 Shares of Stock - MarketBeat
Jennifer Kayden Lee Sells 1,447 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock - MarketBeat
Joseph Shulman Sells 1,281 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock - MarketBeat
Long Term Trading Analysis for (RYTM) - Stock Traders Daily
KBC Group NV Buys 988 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CEO Sells 4,278 Shares of Stock - MarketBeat
JGP Global Gestao de Recursos Ltda. Has $301,000 Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
RYTMRhythm Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
RYTM (Rhythm Pharmaceuticals) Enterprise Value : $3,390.0 Mil (As of Feb. 05, 2025) - GuruFocus.com
Rhythm Pharmaceuticals Inc Azioni (RYTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rhythm Pharmaceuticals Inc Azioni (RYTM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shulman Joseph | Chief Technical Officer |
Feb 19 '25 |
Sale |
57.22 |
1,228 |
70,266 |
8,509 |
| Meeker David P | President and CEO |
Feb 19 '25 |
Sale |
57.22 |
9,896 |
566,249 |
201,281 |
| Lee Jennifer Kayden | EVP, Head of North America |
Feb 19 '25 |
Sale |
57.22 |
2,035 |
116,443 |
5,858 |
| German Christopher Paul | Corporate Controller & CAO |
Feb 19 '25 |
Sale |
57.22 |
635 |
36,335 |
2,070 |
| Cramer Pamela J. | Chief Human Resources Officer |
Feb 19 '25 |
Sale |
57.22 |
982 |
56,190 |
19,209 |
| Smith Hunter C | Chief Financial Officer |
Feb 12 '25 |
Sale |
56.39 |
751 |
42,347 |
105,544 |
| Shulman Joseph | Chief Technical Officer |
Feb 12 '25 |
Sale |
56.40 |
469 |
26,452 |
5,612 |
| Lee Jennifer Kayden | EVP, Head of North America |
Feb 12 '25 |
Sale |
56.39 |
1,815 |
102,348 |
3,598 |
| Lee Jennifer Kayden | EVP, Head of North America |
Feb 13 '25 |
Sale |
58.00 |
1,205 |
69,890 |
2,393 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):